Shots:

• The companies enter into a collaboration to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine). ADC Therapeutics is currently assessing ADCT-402 in P-II study in patients with r/r DLBCL
• Sophia Genetic will analyze cell-free DNA (cfDNA) samples extracted from blood patients participating in ADC Therapeutics’ Phase II study utilizing Sophia’s technology- detecting genomic marker with clinical response to ADCT-402 
• ADCT-402 is an ADC consisting of humanized mAb- binding to CD19 via linker to PBD dimer toxin and is being evaluated in P-Ib (NCT03684694) & P-Ib (NCT03685344) studies in combination with ibrutinib & durvalumab for R/R DLBCL or MCL & R/R DLBCL- MCL- FL respectively

Click here to­ read full press release/ article | Ref: ADC Therapeutics| Image: ADC therapeutics